HRMY · Harmony Biosciences Holdings, Inc. · Executive Compensation
$33.76
-0.04 (-0.12%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.98B
Shares
58.72M
Volume · Nov 13
844.92K
Avg daily vol (3M)
999.19K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jeffrey Dayno | President and Chief Executive Officer | $7,145,170 |
| Kumar Budur | EVP and Chief Medical & Scientific Officer | $5,732,705 |
| Sandip Kapadia | EVP and Chief Financial Officer and Chief Administrative Officer | $3,070,401 |
| Jeffrey Dierks | EVP and Chief Commercial Officer | $2,470,910 |
| Andrew Serafin | EVP, Chief Strategy Officer | $2,087,422 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jeffrey Dierks | EVP and Chief Commercial Officer | $5,597,749 |
| Sandip Kapadia | EVP and Chief Financial Officer and Chief Administrative Officer | $5,580,524 |
| Jeffrey Dayno | President and Chief Executive Officer | $4,450,294 |
| Kumar Budur | EVP and Chief Medical & Scientific Officer | $760,813 |
| Andrew Serafin | EVP, Chief Strategy Officer | $647,425 |
| John C. Jacobs | Former President and Former Chief Executive Officer | $36,634 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sandip Kapadia | EVP and Chief Financial Officer and Chief Administrative Officer | $962,602 |
| Jeffrey Dayno | President and Chief Executive Officer | $762,152 |
| Jeffrey Dierks | EVP and Chief Commercial Officer | $662,099 |
| Andrew Serafin | EVP, Chief Strategy Officer | $605,422 |
| John C. Jacobs | Former President and Former Chief Executive Officer | $514,752 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sandip Kapadia | EVP and Chief Financial Officer and Chief Administrative Officer | $6,223,933 |
| Jeffrey Dierks | EVP and Chief Commercial Officer | $2,700,383 |
| John C. Jacobs | Former President and Former Chief Executive Officer | $885,554 |
| Jeffrey Dayno | Chief Medical Officer | $702,744 |
| Susan Drexler | Former SVP and Chief Financial Officer | $368,549 |
| Andrew Serafin | EVP, Chief Strategy Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| John C. Jacobs | President and Chief Executive Officer | $3,230,734 |
| Jeffrey Dayno | Chief Medical Officer | $2,702,943 |
| Jeffrey Dierks | EVP and Chief Commercial Officer | $2,700,383 |
| Susan Drexler | Former SVP and Chief Financial Officer | — |
| Sandip Kapadia | EVP and Chief Financial Officer | — |
| Andrew Serafin | EVP, Chief Strategy Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| John C. Jacobs | President and Chief Executive Officer | $845,663 |
| Jeffrey Dayno | EVP and Chief Medical Officer | $672,175 |
| Andrew Serafin | EVP and Chief Strategy Officer | — |
| Jeffrey Dierks | EVP and Chief Commercial Officer | — |
| Susan Drexler | Former SVP and Chief Financial Officer | — |
| Sandip Kapadia | EVP and Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Anastasiou | Class I director | Appointed | 2026-10-13 |
| Peter Anastasiou | President and Chief Executive Officer | Appointed | 2026-10-13 |
| Jeffrey M. Dayno, M.D. | Class I director | Resigned | 2026-10-13 |
| Jeffrey M. Dayno, M.D. | President and Chief Executive Officer | Retired | 2026-10-13 |
| Glenn Reicin | Chief Financial Officer | Resigned | 2026-07-16 |
| Glenn Reicin | Chief Financial Officer | Appointed | 2026-04-14 |
| Antonio Gracias | director | Resigned | 2026-04-02 |
| Peter Anastasiou | director | Resigned | 2026-04-02 |
| Troy Ignelzi | director | Appointed | 2026-04-02 |
| Troy Ignelzi | Class III director | Appointed | 2026-04-02 |
| Peter Anastasiou | Class III member of the board of directors | Resigned | 2026-04-02 |
| Peter Anastasiou | Senior Executive Vice President and Chief Operating Officer | Appointed | 2026-04-02 |
| Ron Philip | Class III director | Appointed | 2025-04-03 |
| Adam Zaeske | Executive Vice President and Chief Commercial Officer | Appointed | 2025-03-24 |
| Jack Bech Nielsen | Board | Resigned | 2024-07-01 |
| Kumar Budur, M.D., M.S. | Executive Vice President and Chief Medical & Scientific Officer | Appointed | 2024-05-03 |
| Peter Anastasiou | Class III director | Appointed | 2023-11-08 |
| Sandip Kapadia | Chief Financial Officer and Chief Administrative Officer | Appointed | 2023-10-05 |
| Jeffrey M. Dayno, M.D. | member of the Board | Appointed | 2023-04-24 |
| Jeffrey M. Dayno, M.D. | President and Chief Executive Officer | Appointed | 2023-04-24 |
| Jeffrey M. Dayno | Class I Director | Appointed | 2023-04-24 |
| Jeffrey M. Dayno | President and Chief Executive Officer | Appointed | 2023-04-24 |
| Jeffrey S. Aronin | Executive Chairman | Appointed | 2023-01-06 |
| John C. Jacobs | member of the Board of Directors | Resigned | 2023-01-06 |
| Jeffrey M. Dayno | Interim Chief Executive Officer | Appointed | 2023-01-06 |
Leadership
- Jeffrey Dayno CEO
- Jeffrey M. Dayno CEO, Board Member
- Peter Anastasiou CEO, COO, Board Member
- Jeffrey S. Aronin Chairman
- Glenn Reicin CFO
- Sandip Kapadia CFO
- Susan Drexler CFO
- Eric Motley Board Member
- Linda Szyper Board Member
- Mark Graf Board Member
- Ron Philip Board Member
- Troy Ignelzi Board Member
Key facts
CIK
1802665
CUSIP
413197104
13F (30d)
283 filings
265 filers
Visit website
Investor relations